New analyses on terbinafine susceptibility and MOB-015 published in Journal of Fungi

Barchart · 2d ago

STOCKHOLM, Oct. 5, 2026 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) today announcedthe publication of new analyses demonstrating potent antifungal activity of terbinafine against dermatophytes causing onychomycosis. Importantly, mycological cure with MOB-015 was achieved across the full range of baseline terbinafine susceptibility, including in patients with reduced in vitro susceptibility.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.